Form 8-K - Current report:
SEC Accession No. 0001493152-23-013512
Filing Date
2023-04-25
Accepted
2023-04-25 15:48:06
Documents
15
Period of Report
2023-04-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40079
2 ex99-1.htm EX-99.1 16659
3 ex99-1_001.jpg GRAPHIC 4258
  Complete submission text file 0001493152-23-013512.txt   283776

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lixt-20230424.xsd EX-101.SCH 3990
5 XBRL DEFINITION FILE lixt-20230424_def.xml EX-101.DEF 26651
6 XBRL LABEL FILE lixt-20230424_lab.xml EX-101.LAB 36769
7 XBRL PRESENTATION FILE lixt-20230424_pre.xml EX-101.PRE 25275
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5441
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 23844640
SIC: 2834 Pharmaceutical Preparations